Moolec Science (MLEC) restores Nasdaq listing compliance but faces year of monitoring

Rhea-AI Filing Summary

Moolec Science SA reports that it has regained compliance with all Nasdaq Capital Market continued listing requirements. A Nasdaq Hearings Panel confirmed that the company now meets rules on timely financial reporting, minimum bid price, and minimum stockholders’ equity that were previously cited as deficiencies.

The Panel has imposed a one-year discretionary monitoring period, and Moolec will also be under a mandatory panel monitor for one year relating to its financial reporting and stockholders’ equity requirements. The company plans to keep monitoring its status but cautions there is no assurance it will maintain compliance in the future.

Positive

• Regained full Nasdaq compliance with continued listing standards for financial reporting, minimum bid price, and minimum stockholders’ equity, removing an immediate delisting risk and preserving the company’s Nasdaq Capital Market listing.

Negative

• One-year enhanced monitoring by the Nasdaq Hearings Panel, including a discretionary monitoring period and mandatory panel monitor, and explicit caution that future compliance with all listing requirements is not assured.

Insights

Equity market structure analyst

Moolec regains Nasdaq compliance but faces a year of close monitoring.

Moolec Science has resolved prior Nasdaq deficiencies around financial reporting, minimum bid price, and stockholders’ equity, removing the immediate risk of delisting from the Nasdaq Capital Market. This restores access to that trading venue and its associated liquidity.

However, the Nasdaq Panel imposed both a discretionary monitoring period and a mandatory panel monitor for one year tied to reporting and equity requirements. Any renewed shortfalls during this window could prompt rapid enforcement steps. Future disclosures will show whether Moolec can sustain full compliance over that period.

Key Figures

Panel decision date referenced: January 23, 2026 Discretionary monitoring period: 1 year Mandatory panel monitor period: 1 year

3 metrics

Panel decision date referenced January 23, 2026 Date of Nasdaq Hearings Panel decision setting conditions

Discretionary monitoring period 1 year Nasdaq Listing Rule 5815(d)(4)(A) monitoring from Panel letter date

Mandatory panel monitor period 1 year Covers Rules 5250(c)(1) and 5550(b)(1) from Panel letter date

Key Terms

Nasdaq Capital Market continued listing requirements, Nasdaq Listing Rule 5250(c)(1), Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5550(b)(1), +2 more

6 terms

Nasdaq Capital Market continued listing requirements regulatory

"regained compliance with all previously cited Nasdaq Capital Market continued listing requirements"

Nasdaq Listing Rule 5250(c)(1) regulatory

"including Nasdaq Listing Rule 5250(c)(1) relating to periodic financial reporting"

Nasdaq Listing Rule 5250(c)(1) requires companies listed on the Nasdaq stock exchange to promptly notify the exchange if their stock price falls below a certain minimum level, known as the "initial listing standards." This rule helps ensure that investors are aware of significant declines in a company's stock value, which could signal financial trouble or increased risk. Essentially, it helps maintain transparency and protect investors by keeping them informed about important changes in a company's stock performance.

Nasdaq Listing Rule 5550(a)(2) regulatory

"Nasdaq Listing Rule 5550(a)(2) relating to the minimum bid price requirement"

Nasdaq Listing Rule 5550(b)(1) regulatory

"Nasdaq Listing Rule 5550(b)(1) relating to the minimum stockholders’ equity requirement"

discretionary monitoring period regulatory

"determined to impose a discretionary monitoring period pursuant to Nasdaq Listing Rule 5815(d)(4)(A)"

mandatory panel monitor regulatory

"subject to a mandatory panel monitor pursuant to Nasdaq Listing Rule 5815(d)(4)(B)"

A mandatory panel monitor is an independent group tasked with regularly reviewing safety and key results during a clinical trial or regulated program to protect participants and ensure the study is conducted properly. For investors, this matters because the panel can recommend changes, pauses, or early stopping of a trial — actions that can speed up, delay, or quietly derail a program and therefore materially affect a company’s timeline and value, much like a referee whose calls change the outcome of a game.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-41586

MOOLEC SCIENCE SA

(Exact name of Registrant as Specified in Its Charter)

89 Nexus Way, Camana Bay

Grand Cayman KY1-9009

Cayman Islands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

EXPLANATORY NOTE

The information contained in this Form 6-K and any exhibits hereto shall be deemed to be incorporated by reference into the Company’s registration statement on Form S-8 (Registration No. 333-282263).

Moolec Science SA Regained Compliance with All Nasdaq Capital Market Continued Listing Requirements

On June 1st, 2026, Moolec Science SA (the “Company”) received a letter from the Nasdaq Hearings Panel (the “Panel”) notifying the Company that it has regained compliance with all previously cited Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5250(c)(1) relating to periodic financial reporting, Nasdaq Listing Rule 5550(a)(2) relating to the minimum bid price requirement, and Nasdaq Listing Rule 5550(b)(1) relating to the minimum stockholders’ equity requirement, as required by the Panel’s decision dated January 23, 2026.

The Panel further informed the Company that, although it has regained compliance with the foregoing listing requirements, it has determined to impose a discretionary monitoring period pursuant to Nasdaq Listing Rule 5815(d)(4)(A) for a period of one year from the date of the Panel’s letter. In addition, the Company will be subject to a mandatory panel monitor pursuant to Nasdaq Listing Rule 5815(d)(4)(B) with respect to Nasdaq Listing Rule 5250(c)(1) and Nasdaq Listing Rule 5550(b)(1) for a period of one year from the date of the Panel’s letter.

The Company intends to continue monitoring its compliance with all applicable Nasdaq continued listing requirements. However, there can be no assurance that the Company will be able to maintain compliance with all applicable Nasdaq continued listing requirements in the future.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Moolec Science SA
	(registrant)
Date: June 2, 2026	By:	/s/ Alejandro Antalich
	Name:	Alejandro Antalich
	Title:	Chief Executive Officer

2

FAQ

What did Moolec Science (MLEC) announce in this Form 6-K?

Moolec Science announced it has regained compliance with all Nasdaq Capital Market continued listing requirements. A Nasdaq Hearings Panel confirmed the company now meets reporting, minimum bid price, and stockholders’ equity rules that had previously been cited as deficiencies.

Which Nasdaq listing rules has Moolec Science (MLEC) brought back into compliance?

Moolec Science is back in compliance with Nasdaq Listing Rule 5250(c)(1) on periodic financial reporting, Rule 5550(a)(2) on the minimum bid price requirement, and Rule 5550(b)(1) on the minimum stockholders’ equity requirement, as referenced by the Nasdaq Hearings Panel letter.

Is Moolec Science still under Nasdaq monitoring after regaining compliance?

Yes. The Nasdaq Hearings Panel imposed a one-year discretionary monitoring period and a one-year mandatory panel monitor. The mandatory monitor specifically covers compliance with Nasdaq Listing Rules 5250(c)(1) and 5550(b)(1), increasing oversight during this period despite regained compliance.

How long will Nasdaq’s monitoring of Moolec Science (MLEC) last?

Nasdaq’s discretionary monitoring period will last for one year from the date of the Panel’s letter. In addition, Moolec will be subject to a mandatory panel monitor for one year regarding its financial reporting and minimum stockholders’ equity listing requirements.

Does Moolec Science guarantee it will remain in compliance with Nasdaq rules?

No. Moolec Science states it intends to continue monitoring compliance with all applicable Nasdaq continued listing requirements, but explicitly notes there can be no assurance it will maintain compliance with those requirements in the future.

What is the significance of Moolec Science’s regained Nasdaq compliance for shareholders?

Regained compliance means Moolec’s shares remain listed on the Nasdaq Capital Market, supporting trading access and visibility. However, the one-year monitoring periods and the company’s caution about future compliance indicate that listing status still depends on meeting ongoing financial and reporting standards.